<DOC>
	<DOCNO>NCT00149968</DOCNO>
	<brief_summary>The purpose study ass whether switch mycophenolate mofetil ( MMF ) enteric-coated mycophenolate sodium ( EC-MPS ) result improve GI- and/or health-related quality life outcome , determine proportion renal transplant recipient experience GI complaint MMF-based immunosuppressive treatment .</brief_summary>
	<brief_title>Measurement Patient Reported Gastrointestinal ( GI ) Health-related Quality Life ( HRQL ) Outcomes Renal Transplant Recipients ( MyLife )</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Received kidney transplant least 3 month prior study enrollment Receiving immunosuppressive regimen include MMF combination immunosuppressive drug Receiving MMF least 1 month prior enrollment Patients know hypersensitivity mycophenolic acid , mycophenolate sodium , mycophenolate mofetil component formulation ( e.g . lactose ; see also summary product characteristic ECMPS ) If applicable , GI symptom assume know caused MPA therapy ( e.g . oral biphosphonates induce , infectious diarrhea ) Acute rejection &lt; 1 week prior study enrollment Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Renal transplantation</keyword>
	<keyword>MMF</keyword>
	<keyword>EC-MPS</keyword>
	<keyword>GI problem</keyword>
</DOC>